Bactolife A/S, a Copenhagen, Denmark-based bioindustrial company developing proprietary Binding ProteinsTM, which strengthen the gut microbiome of humans and animals with the aim of reducing the burden of gastrointestinal infections and anti-microbial resistance, raised EUR30M in Series A funding.
The round was led by Athos with participation from the Bill & Melinda Gates Foundation and existing investors, including Novo Holdings.
The company intends to use the funds to advance its most mature projects towards commercial launch and strengthen the technology platform and upscaling capabilities.
Led by Sebastian Søderberg, CEO, Bactolife uses its proprietary Binding Protein technology to develop novel biological solutions, strengthening the gut microbiome and helping solve the challenge of antimicrobial resistance (AMR) development, as well as the general burden of infectious diseases. Its proprietary platform consists of a technology for selecting and producing Binding Proteins that acts on toxins without targeting growth or killing the bacteria directly. Binding Proteins™ are milk-homologous proteins designed to bind to the toxins from gastrointestinal pathogens. They are produced in large scale using state-of-the-art biomanufacturing, making them broadly applicable as part of a normal diet. Binding Proteins™ represent a new paradigm within precision gut microbiome by bringing together state of the art protein science with an affordable, broadly applicable, food and feed product registration.
The company is developing and will market ingredients for Mothers & Children, Elderly, Immunodeficient, Travelers & Deployed and Animal Health. Bactolife has proof of concept (PoC) of its technology among others from testing its most advanced animal health product, Ablacto+ that stabilizes the gut of piglets and reduce the severity of post weaning diarrhea (PWD), in more than 6,000 piglets.
It has approx. 40 employees.
FinSMEs
08/08/2023